Carey K. Anders

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +12

Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression

Carey K. Anders, David S. Hsu, Gloria Broadwater et al. · Journal of Clinical Oncology · 2008 · 913 citations · Full text

Medicine, Cancer Biology, Oncology +17

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin, Virginia F. Borges, Carey K. Anders et al. · Journal of Clinical Oncology · 2020 · 549 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Lisa A. Carey, Donald A. Berry, Constance Cirrincione et al. · Journal of Clinical Oncology · 2015 · 437 citations · Full text

Medicine, Oncology, Pharmacology +17

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Shaveta Vinayak, Sara M. Tolaney, Lee S. Schwartzberg et al. · JAMA Oncology · 2019 · 433 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17